The November DCI Seminar Series, presented by the DCI Cancer Biology Research Program, features Brian Rubin, MD, PhD, Robert J. Tomsich Endowed Chair of Pathology and Laboratory Medicine and chief of the Diagnostics Institute, Cleveland Clinic.
He will present “Lessons learned from the Study of Epithelioid Hemangioendothelioma, a TAZ-CAMTA1/TEAD Addicted Cancer" on November 15, 2023 from 8:00 AM to 9:00 PM at the Searle Center Lecture Hall (level 0).
Rubin specializes in the diagnosis of diseases of bone and soft tissue. He is an expert in the diagnosis and classification of soft tissue neoplasms, especially sarcomas. Rubin is certified by the American Board of Pathology in anatomic pathology and is a founding member of the International Society of Bone and Soft Tissue Pathology. He was a member of the working group that authored the World Health Organisation Classification of Tumours of Bone and Soft Tissue in 2002 and 2012.
Rubin's lab is focused on understanding the pathogenesis of sarcomas with the major aim of developing targeted therapies. He is well known for his work on gastrointestinal stromal tumor (GIST) a cancer that is driven by oncogenically-activated KIT receptor tyrosine kinase. His group also characterized a novel gene fusion in epithelioid hemangioendothelioma (EHE), a sarcoma with endothelial differentiation. This latest development has allowed them to study EHE biology with the subsequent development of disease-specific targeted therapies to treat EHE that are now in Phase I clinical trials. In addition, Rubin led his team in the Robert J. Tomsich Pathology and Laboratory Medicine Institute during the SARS-CoV-2 (COVID) pandemic.
Rubin received his PhD in molecular biology and his MD from Cornell University Medical College. He did his residency in Anatomic Pathology at Brigham and Women’s Hospital and received fellowship training in soft tissue pathology, bone pathology, and cancer genetics.
Email Joan Lofton, MBA, AGM, for the Zoom link at joan.lofton@duke.edu
The monthly DCI Seminar Series is held in conjunction with Hematology Oncology Grand Rounds.
